Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
Patients with end-stage renal disease (ESRD) are at risk of ischemic cardiovascular complications and vascular thrombosis. These observations prompted the present survey of the blood coagulation, fibrinolytic, and inhibitory proteins in a group of 31 ESRD patients and 32 normal controls. Immunologic and functional assays were used to quantitate plasma antigen concentrations and/or functional activities of factors XII, XI, IX, VIII, VII, X, II, and XIII, von Willebrand factor, fibrinogen, fibronectin, high molecular weight kininogen, D-dimer, antithrombin III, protein C, protein S, plasminogen, tissue-type plasminogen activator, plasminogen activator inhibitor, alpha 2-antiplasmin, alpha 1-antitrypsin, and alpha 2-macroglobulin as well as antiplasmin activity. The coagulant activities of factors XII, IX, X, and II were significantly reduced in ESRD patients despite their normal or increased plasma antigen concentrations. In addition, the ESRD patients showed hyperfibrinogenemia and significant elevations of plasma concentrations of D-dimer, von Willebrand factor, factor VII, and factor XIII antigens. They also exhibited significant reductions of antithrombin III, free protein S, plasminogen, and tissue-type plasminogen activator concentrations. Despite ultrafiltration, plasma factor IX activity and von Willebrand factor and fibrinogen concentrations decreased after hemodialysis with little or slight changes in other measured parameters. The ESRD patients studied here exhibited numerous abnormalities of coagulation, fibrinolytic, and inhibitory proteins at multiple levels. These abnormalities may be involved in the pathogenesis of cardiovascular complications and vascular thrombosis in this population. The precise mechanism(s) and clinical significance of the observed abnormalities are unknown and await further investigation.
Vaziri
N D
ND
Department of Medicine, University of California, Irvine, Orange.
Gonzales
E C
EC
Wang
J
J
Said
S
S
D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D007704:Kininogens / Q000097:blood; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis; D015849:Plasminogen Inactivators / Q000032:analysis; D006435:Renal Dialysis; D010959:Tissue Plasminogen Activator / Q000032:analysis; D000979:alpha-2-Antiplasmin / Q000032:analysis
D001779:Blood Coagulation Factors; D005353:Fibronectins; D007704:Kininogens; D015849:Plasminogen Inactivators; D000979:alpha-2-Antiplasmin; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen; D010959:Tissue Plasminogen Activator